749 related articles for article (PubMed ID: 15753357)
21. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
[TBL] [Abstract][Full Text] [Related]
23. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
Haneda H; Sasaki H; Lindeman N; Kawano O; Endo K; Suzuki E; Shimizu S; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Feb; 36(2):69-75. PubMed ID: 16449241
[TBL] [Abstract][Full Text] [Related]
24. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K; Tomizawa K; Mitsudomi T
Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor mutations in lung cancers.
Yatabe Y; Mitsudomi T
Pathol Int; 2007 May; 57(5):233-44. PubMed ID: 17493170
[TBL] [Abstract][Full Text] [Related]
26. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
[TBL] [Abstract][Full Text] [Related]
27. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
Bonanno L; Schiavon M; Nardo G; Bertorelle R; Bonaldi L; Galligioni A; Indraccolo S; Pasello G; Rea F; Favaretto A
Anticancer Res; 2010 Dec; 30(12):5121-8. PubMed ID: 21187500
[TBL] [Abstract][Full Text] [Related]
29. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
30. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
31. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
[TBL] [Abstract][Full Text] [Related]
32. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Shigematsu H; Lin L; Takahashi T; Nomura M; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Shimizu N; Fujisawa T; Feng Z; Roth JA; Herz J; Minna JD; Gazdar AF
J Natl Cancer Inst; 2005 Mar; 97(5):339-46. PubMed ID: 15741570
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lee JW; Soung YH; Seo SH; Kim SY; Park CH; Wang YP; Park K; Nam SW; Park WS; Kim SH; Lee JY; Yoo NJ; Lee SH
Clin Cancer Res; 2006 Jan; 12(1):57-61. PubMed ID: 16397024
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
[TBL] [Abstract][Full Text] [Related]
35. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
37. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
38. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Zhang W; Stabile LP; Keohavong P; Romkes M; Grandis JR; Traynor AM; Siegfried JM
J Thorac Oncol; 2006 Sep; 1(7):635-47. PubMed ID: 17409930
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL; McLellan MD; Zakowski MF; Lash AE; Kasai Y; Broderick S; Sarkaria IS; Pham D; Singh B; Miner TL; Fewell GA; Fulton LL; Mardis ER; Wilson RK; Kris MG; Rusch VW; Varmus H; Pao W
PLoS One; 2007 May; 2(5):e426. PubMed ID: 17487277
[TBL] [Abstract][Full Text] [Related]
40. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
Chantranuwat C; Sriuranpong V; Huapai N; Chalermchai T; Leungtaweeboon K; Voravud N; Mutirangura A
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S322-9. PubMed ID: 16623049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
